Xeplion regulatory update

The Scottish Medicines Consortium reversed a prior decision and recommended use of Xeplion paliperidone palmitate from Johnson & Johnson on the National Health Service (NHS) in Scotland for maintenance treatment of schizophrenia in adult patients stabilized with paliperidone or risperidone. Following a resubmission from the company, the consortium said it recommended the product because it requires less frequent injections compared with a similar medicine and the balance of costs and benefits was favorable. In July, the consortium recommended against the use of the product and said the company did not provide a sufficiently robust economic analysis (see BioCentury, July 18). ...